

CITATION REPORT

List of articles citing

Assessment of liver metabolic function. Clinical implications

DOI: 10.2165/00003088-199427030-00005
Clinical Pharmacokinetics, 1994, 27, 216-48.

Source: <https://exaly.com/paper-pdf/25418539/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
110	Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4Phydroxylation status. 1995 , 58, 143-54		127
109	Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4Phydroxylation. 1995 , 58, 155-64		68
108	The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. 1995 , 40, 523-30		224
107	Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. <i>Clinical Pharmacokinetics</i> , 1995 , 29, 370-91	6.2	158
106	Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. 1995 , 23, 268-277		28
105	Liver function assessment by MEGX. Application to oncology. 1996 , 784, 486-90		4
104	Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. <i>Clinical Pharmacokinetics</i> , 1996 , 31, 9-28	6.2	264
103	Influence of diet and nutritional status on drug metabolism. <i>Clinical Pharmacokinetics</i> , 1996 , 31, 47-64	6.2	142
102	Pharmacokinetics and molecular detoxication. 1996 , 104 Suppl 1, 23-40		63
101	Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. 1996 , 78, 117-22		19
100	Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. 1996 , 59, 376-82		35
99	A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. 1996 , 59, 514-9		83
98	Genotyping of S-mephenytoin 4Phydroxylation in an extended Japanese population. 1996 , 60, 661-6		241
97	The assessment of flavin-containing monooxygenase activity in intact animals. 1996 , 13, 1-28		15
96	Interaction between quinupristin/dalfopristin and cyclosporine. 1997 , 31, 576-8		29
95	Use of probe drugs as predictors of drug metabolism in humans. 1997 , 37, 40S-48S		55
94	Experimental models for evaluating enzyme induction potential of new drug candidates in animals and humans and a strategy for their use. 1997 , 43, 205-29		1

93	Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 210-58	6.2	543
92	Monocrotaline metabolism and distribution in Fisher 344 and Sprague-Dawley rats. 1997 , 117, 115-23		7
91	A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. 1997 , 38, 702-7		43
90	Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. 1997 , 44, 1269-74		4
89	Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4Phydroxylation phenotype and genotype. 1997 , 62, 619-28		78
88	Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. 1997 , 62, 365-76		206
87	Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4Phydroxylation phenotype status. 1997 , 61, 574-82		88
86	Effect of hepatic insufficiency on pharmacokinetics and drug dosing. 1998 , 20, 183-92		55
85	Evaluation of the Carbon 13-Labeled Ketoisocaproate Breath Test To Assess Mitochondrial Dysfunction in Patients with High Alcohol Consumption. 1998 , 22, 1792-1795		15
84	Assessment of the hepatic circulation in humans: new concepts based on evidence derived from a D-sorbitol clearance method. 1998 , 131, 393-405		28
83	The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients. 1998 , 12, 657-65		7
82	Importance of metabolism in pharmacological studies: possible in vitro predictability. 1998 , 25, 705-9		13
81	In vitro and in vivo drug interactions involving human CYP3A. 1998 , 38, 389-430		709
80	Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. 1998 , 27, 119-30		150
79	Heat exposure and drugs. A review of the effects of hyperthermia on pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1998 , 34, 311-22	6.2	53
78	Lack of Pharmacokinetic and Pharmacodynamic Interaction Between Pantoprazole and Glibenclamide in Humans. 1998 , 15, 253-260		8
77	Liver Damage among Environmental Disinfestation Workers. 1998 , 40, 193-197		5
76	Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. 1998 , 44, 914-917		63

75	Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. 1999 , 36 (Pt 6), 722-9	95
74	Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. 1999 , 47, 115-9	37
73	Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. 1999 , 40, 783-7	128
72	A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. 1999 , 24, 272-8	18
71	Technology development in breath microanalysis for clinical diagnosis. 1999 , 133, 218-28	43
70	Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. 2000 , 1, 125-51	87
69	The house musk shrew (<i>Suncus murinus</i>): a unique animal with extremely low level of expression of mRNAs for CYP3A and flavin-containing monooxygenase. 2000 , 126, 225-34	1
68	Effect of liver disease on dose optimization. 2001 , 1220, 247-258	2
67	Genotyping and phenotyping the cytochrome p-450 enzymes. 2002 , 9, 309-16	19
66	Review article: breath testing for human liver function assessment. 2002 , 16, 1977-96	86
65	Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. 2002 , 5, 128-31	15
64	Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition. 2003 , 56, 57-67	28
63	Interactions of herbs with cytochrome P450. 2003 , 35, 35-98	320
62	The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective. 2003 , 43, 443-469	191
61	The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. 2003 , 31, 815-32	667
60	¹³ C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. 2004 , 19, 243	14
59	Special Population Studies In Clinical Development: Pharmacokinetic Considerations. 2004 , 245-305	
58	"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?. 2004 , 44, 120-34	67

57	Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. 2005 , 45, 1434-41		4
56	Liver function evaluation in dogs by the galactose load test. 2005 , 29 Suppl 2, 277-80		2
55	Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 279-304	6.2	349
54	Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 977-88	6.2	34
53	Detoxification and biotransformational imbalances. 2006 , 2, 122-40		18
52	Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. 2006 , 26, 439-44		1
51	L-[1-(13)C] phenylalanine breath test for monitoring hepatic function after living donor liver transplant surgery. 2007 , 1, 026002		6
50	Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. 2008 , 64, 1147-61		428
49	Pharmacokinetics in special populations. 2009 , 41, 422-54		15
48	The LiMAX test: a new liver function test for predicting postoperative outcome in liver surgery. 2010 , 12, 139-46		147
47	Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes. 2012 , 13-80		
46	Liver involvement in hereditary hemorrhagic telangiectasia: can breath test unmask impaired hepatic first-pass effect?. 2012 , 7, 323-9		8
45	N-Acetyltransferase2 (Genotypisierung) [Biomonitoring Methods in German language, 2004]. 2012 , 1-25		
44	N-Acetyltransferase 2 (Phänotypisierung: Coffein-Test) [Biomonitoring Methods in German language, 2004]. 2012 , 1-19		
43	N-Acetyltransferase 2 (phenotyping: caffeine test) [Biomonitoring Methods, 2004]. 2012 , 165-182		
42	N-Acetyltransferase 2 (genotyping) [Biomonitoring Methods, 2004]. 2012 , 135-163		
41	Critical appraisal of 13C breath tests for microsomal liver function: aminopyrine revisited. 2014 , 34, 487-94		12
40	Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic Fatty liver disease. 2014 , 48, 59-65		6

39	Pharmacokinetic evaluation of C-3 modified 1,8-naphthyridine-3-carboxamide derivatives with potent anticancer activity: lead finding. 2014 , 29, 710-21	8
38	Dynamic carbon 13 breath tests for the study of liver function and gastric emptying. 2015 , 3, 12-21	33
37	Variations of pharmacokinetics of drugs in patients with cirrhosis. 2016 , 9, 441-58	11
36	Transcriptome profiling of the liver among the prenatal and postnatal stages in chickens. 2019 , 98, 7030-7040	11
35	Alpha-l-fucosidase: a novel serum biomarker to predict prognosis in early stage esophageal squamous cell carcinoma. 2019 , 11, 3980-3990	7
34	Hepatic progenitor cell activation is induced by the depletion of the gut microbiome in mice. 2019 , 8, e873	5
33	Korean Red Ginseng and Korean black ginseng extracts, JP5 and BG1, prevent hepatic oxidative stress and inflammation induced by environmental heat stress. 2020 , 44, 267-273	6
32	Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis. 2020 , 8,	1
31	Hepatoprotective effect of plant polysaccharides from natural resources: A review of the mechanisms and structure-activity relationship. 2020 , 161, 24-34	32
30	AFB1 Induced Transcriptional Regulation Related to Apoptosis and Lipid Metabolism in Liver of Chicken. 2020 , 12,	9
29	Long Non-coding RNA and mRNA Profile of Liver Tissue During Four Developmental Stages in the Chicken. 2020 , 11, 574	4
28	Evaluation of Acute and Subacute Toxicity of Two Different Extracts from Que Zui Tea in Rats. 2021 , 2, 81	2
27	Dynamic and Continuous Monitoring of Renal and Hepatic Functions with Exogenous Markers. 2002 , 31-72	1
26	Mechanisms of Drug Interactions. 2001 , 13-38	3
25	Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion. 2011 , 11-41	1
24	Comments to "interaction between caffeine and clozapine". 1995 , 15, 376-7	9
23	Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. 1996 , 18, 393-6	81
22	The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. 1996 , 18, 586-91	42

21	Determination of antipyrine and metabolites in plasma of a patient with mild renal failure. 1997 , 19, 705-10		4
20	Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. 1998 , 20, 371-5		23
19	Pharmacokinetics of Drug Metabolites. 1999 , 1-47		2
18	Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. 2003 , 9, 359-63		54
17	Dosisanpassung bei Leberinsuffizienz. 2000 , 70-79		1
16	Klinisch-chemische Untersuchungen. 2003 , 198-231		
15	Dosisanpassung bei Leberinsuffizienz. 2003 , 80-87		1
14	Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. 2006 , 060224014707001		
13	Tests of Liver Function. 2010 , 333-343		
12	^{13}C -methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis. 2013 , 157, 392-400		1
11	Stand der klinischen Forschung bei den NMDA-Rezeptorantagonisten im Neugeborenen- und Kindesalter. 1995 , 101-119		
10	Pharmakogenetik. 1996 , 101-120		2
9	Fremdstoffmetabolismus und Krebs: Molekular-epidemiologische Forschung. 1998 , 218-259		
8	Quantification of ex vivo tissue activity by short and long time-course analysis of multifunctional OCT signals. 2020 ,		1
7	Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. <i>American Journal of Human Genetics</i> , 1997 , 60, 284-95	11	635
6	Exploring of blood viscosity in injured liver tissues of hyperlipidemic mice. <i>Dyes and Pigments</i> , 2022 , 202, 110272	4.6	0
5	Data_Sheet_1.docx. 2020 ,		
4	Data_Sheet_1.ZIP. 2020 ,		

- 3 A review on nutritional composition, health benefits and potential applications of by-products from pea processing. 1
- 2 Liver fat accumulation more than fibrosis causes early liver dynamic dysfunction in patients with non-alcoholic fatty liver disease. **2022**, 0
- 1 Acidic polysaccharide from corn silk: Structural & conformational properties and hepatoprotective activity. **2023**, 236, 123851 0